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Pancreatic cancer remains one of the most lethal cancers. 
These patients often have multiple symptoms, and integrated 
supportive care is critical in helping them remain well for as 
long as possible. Fluorouracil-based chemotherapy is known 
to improve overall survival (OS) by approximately 3 months, 
compared to the best supportive care alone. A 1997 study 
comparing gemcitabine and fluorouracil treatment of ad-
vanced pancreatic cancer patients showed an improvement 
in OS of 1 month in patients receiving gemcitabine. Over the 
next 10 years, multiple randomized studies compared single-
agent gemcitabine with combination chemotherapy and 
showed no effective survival improvement. However, the ad-
dition of erlotinib, an epidermal growth factor receptor (EGFR) 
inhibitor, was associated with a significant improvement in 
OS of approximately 2 weeks. However, adoption of this regi-
men has not been widespread because of its limited effect 
and added toxicity. Two clinical trials have recently prolonged 
OS in advanced pancreatic cancer patients by almost 1 year. 
The first compared FOLFIRINOX with gemcitabine alone, 
and was associated with a significant improvement in me-
dian survival. The second compared gemcitabine and nab-
paclitaxel with gemcitabine alone, and was associated with 
improvements in OS. At present, these regimens are consid-
ered standard treatment for patients with good performance 
statuses. (Gut Liver 2016;10:340-347)
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INTRODUCTION
The prognosis for pancreatic cancer patients is very poor. 
Patients with locally advanced disease have a median survival 
time of 8 to 12 months, and patients with distant metastasis 
have significantly worse outcomes, with a median survival time 
of only 3 to 6 months.1
Most patients (80%) present with inoperable advanced pan-
creatic cancer at initial diagnosis; their management is a sig-
nificant unmet challenge. Chemotherapy remains the mainstay 
of treatment for patients presenting with advanced pancreatic 
cancer, resulting in an increase in overall survival (OS). It is the 
eighth leading cause of death from cancer in men and the ninth 
leading cause of death from cancer in women throughout the 
world.1 In the Republic of Korea, approximately 5,400 people 
develop exocrine pancreatic cancer each year, and because of its 
aggressive character and the fact that most patients present with 
relatively advanced disease, most of them die from the disease.2 
Recently completed phase III clinical trials have shown that 
an increasing number of chemotherapeutic options are now 
available for patients with advanced pancreatic cancer. These 
modern chemotherapy regimens are associated with a median 
survival approaching 1 year in selected patients with advanced 
pancreatic cancer,3 and we are now starting to think strategi-
cally about how to apply these different regimens to pancreatic 
cancer patients (Fig. 1).
Despite these advances in treatment options, the number of 
pancreatic cancer-related deaths continues to increase, and pan-
creatic cancer is expected to represent the second-leading cause 
of cancer-related mortality in the United States by the year 
2020.4 This trend reflects the limitations of the current thera-
peutic regimens, the characteristics of pancreatic cancer (which 
is generally diagnosed at an advanced stage), and the absence 
of effective biomarkers. This article reviews the past and current 
systemic chemotherapy regimens used to treat patients with ad-
vanced pancreatic cancer. In addition, we will briefly discuss the 
issues of current alternative treatments, such as immunotherapy, 
epigenetic therapy, and stromal therapy, even though these are 
beyond the scope of our review.
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correspondence to: Seung Woo Park
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 
03722, Korea 
Tel: +82-2-2228-1964, Fax: +82-2-393-6884, E-mail: swoopark@yuhs.ac
Received on September 16, 2015. Accepted on December 1, 2015.
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl15465
Lee HS and Park SW: Systemic Chemotherapy in Advanced Pancreatic Cancer  341
CHEMOTHERAPY APPROACHES
The primary goals of treatment for advanced pancreatic 
cancer are palliation and lengthened survival. At first, systemic 
chemotherapy treatment is recommended for patients with ad-
vanced pancreatic cancer and good performance statuses and 
is expected to result in prolonged survival. Depending on a pa-
tient’s performance status, physicians can consider single agent 
or combination chemotherapy for this initial therapy. After 
cancer progression, second-line chemotherapy is also possible, 
especially in patients who maintain a good performance status. 
In the past, single agent chemotherapy has been the main-
stay treatment for advanced pancreatic cancer. However, no 
single agent gave consistent median survival durations above 
7 months (Table 1). And then, combination chemotherapy has 
become a new alternative in patients with advanced pancreatic 
cancer, with an increased survival benefit (Table 2). 
1. Fluorouracil
Until 1997, fluorouracil (5-FU) was extensively studied using 
a variety of doses and schedules, but the response rate was very 
low (0% to 10%), there was no consistent effect on disease-
related symptoms.5,6
1) Capecitabine 
Capecitabine is a rationally designed oral fluoropyrimidine 
that is reliably absorbed intact through the intestinal wall and 
then converted to 5-FU. It is present at consistently higher levels 
in tumor rather than normal tissue, thereby providing the basis 
for enhanced selectivity and better tolerability.7 The efficacy of 
capecitabine monotherapy was shown in a study with advanced 
pancreatic cancer:8 three (7.3%) of the 41 patients had an ob-
jective response and 10 (24%) of the 41 patients experienced a 
clinical benefit response by improvement in pain intensity, an-
algesic consumption, and Karnofsky performance status. 
2) S-1 
S-1 is an oral fluoropyrimidine that includes three different 
agents (tegafur, gimeracil, and oteracil). S-1 monotherapy rep-
resents a reasonable alternative for patients who are not can-
didates for a more intensive first-line chemotherapy and who 
prefer the convenience of an oral regimen. In the phase III GEST 
trial of patients with locally advanced or metastatic pancreatic 
cancer, S-1 monotherapy was compared to either gemcitabine 
monotherapy or S-1 plus gemcitabine combination therapy.9 
The OS in patients treated with S-1 were non-inferior to those 
with gemcitabine monotherapy (9.7 months vs 8.8 months, 
p<0.001 for non-inferiority), and the objective response rate 
was significantly higher with S-1 treatment (21% vs 13%). 
3) 5-FU plus doxorubicin and mitomycin (FAM)
Despite essentially equivalent objective response rates and 
palliative effects (improved performance, body weight, or symp-















nab-paclitaxel Fig. 1. The trends of chemothera-
peutic agents in advanced pancreatic 
cancer.
5-FU, 5-fluorouracil.
Table 1. Randomized Controlled Trials of Monotherapy
Regimen 5-FU Gemcitabine Capecitabine
Study phase III III II
Patients enrolled, n  126  126  42
Response rate, %  0  5.4  9.5
Median survival, mo 4.4  5.6  6.0
Time to progression, mo 0.9  2.1 NR
Clinical benefit response, % 4.8 23.8 24.0 
5-FU, 5-fluorouracil; NR, not reported.
Table 2. Randomized Controlled Trials of Combination Chemotherapy Compared with Gemcitabine Monotherapy
Regimen Gemcitabine+erlotinib Gemcitabine+capecitabine FOLFIRINOX Gemcitabine+nab-paclitaxel
Year 2007 2009 2011 2013
Study phase III III III III
Patients enrolled, n 569 533 342 861
Response rate, % 8.6 vs 8.0 19.1 vs 12.4 31.6 vs 9.4 23.0 vs 7.0
Median survival, mo 6.3 vs 5.9 
(p=0.038)
7.1 vs 6.2 
(p=0.08)
11.1 vs 6.8 
(p<0.001)
  8.5 vs 6.7
(p<0.001)
Time to progression, mo 3.7 vs 3.5 5.3 vs 3.8 6.4 vs 3.3  5.5 vs 3.7
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5-FU based combination regimens compared to 5-FU alone. 
Because of the failure to produce improved survival or pallia-
tion, the unrewarded toxicity, and the excessive cost, the FAM 
regimen was not recommended for the treatment of advanced 
pancreatic cancer.10
4) Methotrexate plus 5-FU, cyclophosphamide, vincristine, 
and mitomycin C (Mallinson regimen)
A phase III trial evaluated the Mallinson regimen and showed 
objective response rates of 21% and a median survival of 4.5 
months, but this regimen was associated with significantly in-
creased toxicity. Despite the higher objective response rates, this 
combination regimen did not give a survival advantage com-
pared to 5-FU alone.11 
2. Gemcitabine
In 1997, a clinical trial was performed to assess the effective-
ness of gemcitabine in patients with newly diagnosed advanced 
pancreatic cancer. The trial randomly assigned 126 previously 
untreated patients with locally advanced or metastatic pancre-
atic cancer to 5-FU or gemcitabine treatment.12 The primary 
efficacy measures of the trial were the clinical benefit response 
associated with pain (analgesic consumption and pain intensity), 
the Karnofsky performance status, and weight. Other measures 
of efficacy included the response rate, the time to progressive 
disease, and the survival. Gemcitabine was associated with sig-
nificantly better clinical response (24% vs 5%, p=0.0022) and 
median OS (5.6 months vs 4.4 months, p=0.0025). Based on 
these significant improvements in clinical benefit and survival, 
gemcitabine was approved as a first-line therapy for advanced 
pancreatic cancer.
1) Gemcitabine plus 5-FU 
Gemcitabine has been combined with both bolus and infu-
sional 5-FU. In a phase III trial, 5-FU and gemcitabine combined 
treatment did not improve the median survival of patients with 
advanced pancreatic carcinoma when compared with single-
agent gemcitabine treatment (median survival, 6.7 months vs 5.4 
months; p=0.09).13
2) Gemcitabine plus capecitabine 
For patients who want to gain some survival benefit from 
a less toxic regimen, gemcitabine plus capecitabine treatment 
may be an acceptable option. In 2007, a phase III trial com-
pared the efficacy and safety of the combined gemcitabine 
plus capecitabine versus single-agent gemcitabine treatment in 
advanced pancreatic cancer. Median survival was not signifi-
cantly improved by the addition of capecitabine in this trial (8.4 
months vs 7.2 months, p=0.234).14 However, a second European 
trial found that progression-free survival (PFS) and objective 
response rates were significantly improved in patients receiving 
gemcitabine plus capecitabine when compared with gemcitabine 
treatment alone. The second trial also showed a trend towards 
an improvement in OS, even if it did not reach statistical sig-
nificance (hazard ratio [HR], 0.86; 95% confidence interval [CI], 
0.72 to 1.02; p=0.08).15 Moreover, a meta-analysis of the two 
phase III trials showed a significant survival benefit in favor of 
gemcitabine plus capecitabine (HR, 0.86; 95% CI, 0.75 to 0.98; 
p=0.02). The combination of gemcitabine plus capecitabine 
may be considered a standard first-line treatment option for ad-
vanced pancreatic cancer.
3) Gemcitabine plus S-1 
In a phase III GEST trial, S-1 plus gemcitabine combined 
treatment was directly compared to gemcitabine monotherapy 
in patients with advanced pancreatic cancer. For the primary 
endpoint of OS, the combination (gemcitabine plus S-1) was not 
found to be superior to gemcitabine monotherapy (median, 10.1 
months vs 8.8 months; HR, 0.88; 95% CI, 0.71 to 1.08; p=0.15).9
4) Gemcitabine plus cisplatin 
Three phase III trials have compared gemcitabine treatment 
alone to the combination of gemcitabine plus cisplatin,16-18 but 
no significant survival advantage was achieved with this treat-
ment approach (median survival, 7.9 months vs 7.7 months; 
p=0.857). Nevertheless, selected patients with inherited forms of 
pancreatic cancer may have survival benefits when treated with 
platinum-based agent.19 
5) Gemcitabine plus irinotecan
In 2006, a phase III trial was performed to determine the 
response rate and median and OS of gemcitabine as a mono-
therapy versus gemcitabine plus irinotecan combined treatment 
in advanced pancreatic cancer. No statistically significant differ-
ence was observed in this study with respect to OS (6.4 months 
vs 6.5 months).20
6) Gemcitabine plus cisplatin, epirubicin and 5-FU (PEFG)
In a randomized multicenter phase III trial, patients were 
randomly assigned to the PEFG regimen or gemcitabine mono-
therapy. The PEFG regimen was associated with a significantly 
higher response rate (39% vs 9%) and 4-month PFS (primary 
endpoint, 60% vs 28%).21 However, more patients in the PEFG 
group had grade 3 to 4 neutropenia (43% vs 14%) and throm-
bocytopenia (30% vs 1%) than patients in the gemcitabine 
monotherapy group (p<0.0001).
7) Gemcitabine plus oxaliplatin (GEMOX)
The efficacy of GEMOX was compared to gemcitabine treat-
ment alone in two different multicenter trials of patients with 
advanced pancreatic cancer. In the first clinical trial, GEMOX 
was associated with significantly higher response rates (27% 
vs 17%) and significantly longer median PFS (5.8 months vs 
3.7 months), but only a trend towards improved median sur-
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vival compared to gemcitabine monotherapy (9 months vs 7.1 
months, p=0.13).22 In the second clinical trial of 832 patients 
with advanced pancreatic cancer, GEMOX did not show an 
improvement in median survival or any symptom benefit over 
standard gemcitabine monotherapy (5.7 months vs 4.9 months, 
p=0.22).23 There were also no significant benefits for GEMOX 
treatment in terms of objective response rate (9% vs 6%) or PFS.
8) Gemcitabine plus erlotinib 
Since 1997, gemcitabine has been combined with many other 
cytotoxic agents including 5-FU, cisplatin, docetaxel, oxalipla-
tin, and irinotecan. Despite encouraging early phase data, phase 
III randomized trials of such combinations have not demon-
strated a statistically significant survival benefit compared to 
treatment with gemcitabine alone. 
On the other hand, pancreatic cancers often express recep-
tors for epidermal growth factor (EGF). A phase III trial directly 
compared gemcitabine treatment with and without erlotinib (an 
inhibitor of epidermal growth factor receptor [EGFR] tyrosine 
kinase) in patients with advanced pancreatic cancer.24 Combined 
therapy showed a statistically significant improvement in OS 
compared to gemcitabine treatment alone (HR, 0.82; p=0.038; 
median, 6.2 months vs 5.9 months, respectively). PFS was also 
significantly longer with gemcitabine plus erlotinib combined 
treatment, with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; 
p=0.004).
Erlotinib was eventually approved for use in the United States 
for the treatment of advanced pancreatic cancer in combination 
with gemcitabine. However, there were some limitations. The 
combination of gemcitabine plus erlotinib treatment resulted 
in just a 2-week improvement in survival over gemcitabine 
treatment alone. Furthermore, the high percentage of activating 
KRAS mutations, which occur in up to 90% of pancreatic can-
cer patients, means that the pharmacological inhibition of EGFR 
upstream of KRAS remains only marginally effective in this 
cancer type.25 
3. Taxanes
Taxanes have shown limited benefit as monotherapies in 
advanced pancreatic cancer. In one phase II study, in which 33 
patients with advanced pancreatic cancer received single agent 
docetaxel treatment along with granulocyte colony stimulat-
ing factor, the objective response rate was only 6%. However, 
a disease-stabilizing effect was suggested because the 1-year 
survival was 36% with clinical benefit.26 However, other stud-
ies have reported limited activity of taxanes as single agents 
against pancreatic cancer.
4. Irinotecan
Irinotecan has limited activity as a monotherapy in advanced 
pancreatic cancer, with low response rates of 9% and median 
survival duration of 5.2 months.27 Topotecan has showed a 
total response rate of 8% and stable disease was seen in three 
patients. The median survival was 20 weeks. The time to pro-
gression and the median survival reported are similar to those 
observed with gemcitabine monotherapy in a randomized trial, 
suggesting that topotecan also has limited activity in advanced 
pancreatic cancer.28 
TWO RECENT CLINICAL TRIALS SUPERIOR TO  
GEMCITABINE ALONE
1. The FOLFIRINOX regimen
Newer regimens including 5-FU/leucovorin, oxaliplatin, and 
irinotecan (FOLFIRINOX) showed promising results for ad-
vanced pancreatic cancer. The randomized phase III trial evalu-
ated FOLFIRINOX treatment versus gemcitabine monotherapy in 
chemotherapy-naïve patients with advanced pancreatic cancer, 
good performance statuses, and serum bilirubin <1.5 times the 
upper limit of normal. The results showed dramatic improve-
ments in both median PFS (6.4 months vs 3.3 months, p<0.001) 
and median OS (11.1 months vs 6.8 months, p<0.001).3 The 
trial was stopped after enrolling only 250 patients, when a pre-
planned interim analysis demonstrated that the primary trial 
endpoint (improved OS) had been met. 
Treatment-related toxicity was, however, also significantly 
worse with FOLFIRINOX treatment, including grade 3/4 neutro-
penia (45.7%), thrombocytopenia (9.1%), and diarrhea (12.7%). 
These data eventually established FOLFIRINOX as the preferred 
first-line therapy for patients with advanced pancreatic cancer 
who have a good performance status.
2. Gemcitabine plus nab-paclitaxel 
Gemcitabine plus nanoparticle albumin bound (nab)-paclitaxel 
represents an acceptable alternative to FOLFIRINOX. Von Hoff 
et al.29 reported promising results from the Metastatic Pancreatic 
Adenocarcinoma Clinical Trial (MPACT), an international phase 
III study in which 861 patients were randomly assigned to re-
ceive either gemcitabine treatment alone or the combination 
of gemcitabine plus nab-paclitaxel. The addition of this taxane 
agent resulted in a significant improvement in OS (8.5 months 
vs 6.7 months; p<0.001; HR, 0.72; 95% CI, 0.62 to 0.83), with a 
manageable and predictable toxicity profile. Grade 3/4 adverse 
events, that were seen more often with this combination ther-
apy, included neutropenia (38% vs 27%), febrile neutropenia 
(3% vs 1%), and diarrhea (6% vs 1%). Some studies investigated 
the biological effects of this regimen and suggested that tumors 
treated with nab-paclitaxel contained fewer cancer associated 
fibroblasts and a clearly altered collagen that results in tumor 
softening at the tissue level.29 
In addition to the hypothesis that the tumor cells themselves 
are albumin-avid leading to enhanced tumoral concentration, it 
has been hypothesized that osteonectin—a secreted protein that 
is acidic and rich in cysteine, and which is highly expressed and 
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secreted by pancreatic peritumoral fibroblasts—may serve as 
an albumin-binding protein that sequesters nab-paclitaxel and 
concentrates the drug intratumorally.30
SECOND-LINE SYSTEMIC CHEMOTHERAPY 
For patients who are refractory to a gemcitabine-containing 
regimen, a limited amount of data suggest that a second-line 
chemotherapy may improve survival and it is, therefore, reason-
able to consider further chemotherapy in patients who maintain 
a good performance status. For patients with advanced disease 
who have received prior gemcitabine-based therapy, fluoropy-
rimidine-based chemotherapy regimens are acceptable second-
line options. Alternatively, gemcitabine-based therapy can be 
given to those previously treated with fluoropyrimidine-based 
therapy. However, there are no widely accepted optimal regi-
mens for second-line therapy. 
There are few randomized trials of second-line chemotherapy 
for patients who have failed a gemcitabine-based chemo-
therapy. A phase II trial was conducted to explore the efficacy 
of capecitabine and oxaliplatin (XELOX) in patients with ad-
vanced pancreatic cancer who were previously treated with 
gemcitabine. The Kaplan-Meier estimate of the overall median 
survival was 23 weeks (95% CI, 17.0 to 31.0 weeks). The XE-
LOX regimen is active in gemcitabine-pretreated patients with 
advanced pancreatic cancer, especially in patients with a good 
performance status and those who have responded to first-line 
chemotherapy.31
A phase III trial comparing the OFF regimen (oxaliplatin, 
5-FU, and folinic acid) to best supportive care provided first-
time evidence for the benefit of second-line chemotherapy in 
advanced pancreatic cancer, manifested by prolonged second-
line survival (4.8 months vs 2.3 months, p=0.008) and median 
OS (9.1 months vs 7.9 months, p=0.031).32 The AIO-PK0104 trial 
also assessed second-line therapy in a randomized crossover 
trial and found capecitabine to be efficacious after progression 
in patients with advanced disease on gemcitabine and erlotinib 
combined primary treatment.33 On the other hand, the optimal 
second-line chemotherapy for patients who fail initial FOLFIRI-
NOX treatment is undefined. For those patients who retain a 




New systemic therapies have been designed based upon the 
biological properties of pancreatic cancer. The KRAS onco-
gene has been the subject of considerable research over the 
last decade. KRAS proteins are membrane-bound GTP-binding 
proteins that act as molecular switches in downstream signal 
transduction.34 Mutations of the KRAS gene, present in ap-
proximately 90% of pancreatic cancers, lead to the constitutive 
activation of these proteins and tumorigenesis.35 
In order to become active, KRAS proteins require the post-
translational addition of a 15-carbon farnesyl group. If the addi-
tion of this farnesyl group is blocked, the protein cannot attach 
to the cell membrane and the protein remains inactive. Farnesyl 
transferase inhibitors were designed to prevent membrane as-
sociation and thereby activation of KRAS. However, the oral 
farnesyl transferase inhibitor R115777 did not increase the me-
dian survival time of patients with advanced pancreatic cancer 
(112 days vs 109 days, p=0.75). It is likely that nonfarnesylated 
KRAS can still undergo prenylation, via geranylgeranylation, to 
associate with the cell membrane.34,36
2. EGFR and VEGF
As noted above, the combination of gemcitabine plus erlo-
tinib resulted in a modest 2-week improvement in survival over 
gemcitabine treatment alone in a phase III trial. Since then, nu-
merous EGFR or vascular endothelial growth factor (VEGF) tar-
geted agents have been evaluated, alone or in combination with 
chemotherapy, in advanced pancreatic cancer. Unfortunately, 
most agents have failed to improve patient survival signifi-
cantly. The list of agents tested in trials include antiangiogenic 
drugs, such as bevazicumab; monoclonal antibodies directed 
against EGFR, such as cetuximab; and multikinase inhibitors 




The extensive desmoplastic reaction that comprises up to 90% 
of the tumor volume is the predominant histological feature of 
pancreatic cancer. Inefficient drug delivery due to the intense 
stromal reaction may be an important contributor to chemore-
sistance in pancreatic cancer.42 The inhibition of stroma-related 
signaling pathways is considered to be a promising tool to de-
crease stromal density and to facilitate the access of cytotoxic 
drugs to the tumor cells.
The sonic hedgehog pathway is one of the predominant 
signaling cascades known to stimulate the stromal reaction. 
Treatment with the hedgehog inhibitor IPI926 resulted in a 
significant depletion of tumor-associated stroma. However, the 
interim analysis of a clinical trial found that the OS of patients 
on the gemcitabine plus IPI926 treatment arm was inferior to 
that of patients treated with gemcitabine plus placebo. On the 
other hand, clinical trials for other hedgehog inhibitors, such 
as GDC-0449 in combination with gemcitabine or LDE225 in 
combination with FOLFIRINOX or gemcitabine, are still ongoing 
(NCT01088815, NCT02358161).
The transforming growth factor β (TGF-β)-dependent signal-
ing cascade is known to be another key pathway implicated 
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in the stromal reaction which is associated with invasion, me-
tastasis, angiogenesis, and escape from immune-surveillance 
in pancreatic cancer.43,44 A phase I/II trial is currently ongoing 
to test the impact of LY2157299—a small molecule that has 
been designed to selectively inhibit the TGF β type I receptor—
in combination with gemcitabine treatment for patients with 
advanced pancreatic cancer (NCT01373164). Acellular matrix 
components are currently being evaluated as targets for thera-
peutic intervention. Human recombinant PH20 hyaluronidase 
(PEGPH20) enzymatically depletes hyaluronan (highly abundant 
in the extracellular matrix of both human and murine pancre-
atic cancer tissues), thereby inducing the re-expansion of tumor 
blood vessels and increasing the concentration of gemcitabine 
within the tumor.45 PEGPH20 resulted in significantly dimin-
ished tumor growth and prolonged survival in mice. A phase II 
trial comparing PEGPH20 treatment combined with gemcitabine 
plus nab-paclitaxel versus gemcitabine plus nab-paclitaxel 
treatment alone is currently recruiting to evaluate the impact of 
depleting hyaluronan in patients with advanced pancreatic can-
cer (NCT01839487).
2. Immunotherapy
Immunotherapy stimulates a host immune response that 
results in long-term tumor destruction. The stroma of pancre-
atic cancer is particularly rich in inflammatory cells that are 
proposed to mediate drug resistance and tumor progression. 
Therefore, immune cells—such as T-cells and macrophages— 
infiltrating the peri-tumoral stroma represent a promising target 
for immunotherapeutic approaches.46,47
T-cell mediated immunity includes multiple sequential steps 
that are regulated by counterbalancing stimulatory and in-
hibitory signals that fine-tune the response. These inhibitory 
pathways are referred to as immune checkpoints and these 
are crucial for maintaining self-tolerance and modulating the 
duration and amplitude of physiological immune responses. 
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is one 
of these immune checkpoints that plays a critical role in regu-
lating and limiting immune responses, and it can be blocked by 
specific antibodies such as ipilimumab, a fully human antibody. 
The binding of ipilimumab to CTLA-4 blocks the immune limit-
ing activity of CTLA-4, thereby sustaining an active immune 
response against the cancer cells. Early phase trials are currently 
underway in pancreatic cancer for ipilimumab (NCT01473940). 
Another promising immunomodulatory target is CD40, which 
is a costimulatory molecule for antigen presenting cells. Gem-
citabine treatment combined with CD40 agonist-activated T-
cells reduced the tumor burden in advanced pancreatic cancer 
patients in a phase I study by decreasing tumor stroma and 
increasing the tumor infiltration of activated macrophages.48
In addition to enhancing the systemic immune response, 
attracting selected antitumor cytokines is also a promising 
concept that is currently under intense preclinical and clinical 
investigation. One of the most tumor selective antigens that 
can be used to guide cytokines to the site of a tumor is the 
extradomain B (ED-B) of fibronectin. The fusion product con-
sisting of the ED-B antibody fragment L19 and interleukin-2 is 
currently being tested in a phase I/II trial in pancreatic cancer 
(NCT01198522).
3. Histone deacetylase inhibitor
Chromatin is formed by the wrapping of DNA around his-
tones, a process that is regulated by histone acetylation status. 
The acetylation of histones removes their positive charge, lead-
ing to a more relaxed chromatin structure that is associated 
with transcriptionally active DNA. This relaxation can be re-
versed by histone deacetylases (HDAC). Epigenetic regulation of 
tumor suppressor genes via HDAC is involved in the apoptosis, 
differentiation, and growth of cells, all of which influence tumor 
cell survival. HDAC inhibitors, such as vorinostat, have been 
developed and have demonstrated significant antitumor activity 
in a variety of malignancies. In pancreatic cancer, vorinostat is 
currently being evaluated in combination with radiation therapy 
and chemotherapy in phase I/II clinical trials (NCT00243100, 
NCT00978688). 
4. Telomerase peptide vaccine
Telomerase is a ribonucleotide enzyme that maintains cel-
lular stability and is expressed by almost all cancer cells.49 A 
phase III trial was performed to assess the efficacy and safety of 
telomerase peptide vaccine (GV1001) in combination with che-
motherapy (gemcitabine and capecitabine) treatment in patients 
with advanced pancreatic cancer. However, adding GV1001 
vaccination to chemotherapy (gemcitabine and capecitabine) 
treatment did not improve OS in these patients.
Despite the disappointing phase III results, the findings have 
identified biomarkers that may predict response to this vaccine 
and new research may indicate benefits in a subgroup of pa-
tients. Baseline eotaxin levels were measured in patients receiv-
ing concurrent chemoimmunotherapy. High eotaxin levels may 
predict an improved survival in patients receiving GV1001 with 
gemcitabine and capecitabine treatment (high eotaxin, 14.8 
months; low eotaxin, 7.9 months; p=0.0135). There is another 
ongoing study with chemoradiotherapy in patients with locally 
advanced pancreatic cancer (NCT01342224).50
CONCLUSIONS
Despite multiple clinical trials and continuous efforts, pan-
creatic cancer remains one of the most difficult cancers to cure, 
both because of its resistance to conventional chemotherapy 
and because of its aggressive characteristics. Recent clinical 
trials have shown that newly combined chemotherapies can 
prolong OS in advanced pancreatic cancer.3,51 These therapeu-
tic advances are more likely to produce gradual improvements 
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in patient outcomes, rather than innovative change. Although 
conventional chemotherapy remains the standard of care for 
advanced pancreatic cancer, a variety of novel therapeutic 
approaches—including signal transduction inhibitors, immu-
notherapy, stromal depleting agents, and epigenetic therapy—
are currently under active investigation. Several studies have 
already demonstrated encouraging results in phase I/II studies. 
In the future, these new insights into the biology and genetics 
of pancreatic cancer may be of value in the development of new 
chemotherapeutic regimens. 
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